The Science Behind Kiro

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce remarkable weight loss — 15 to 21% of body weight in major clinical trials. But body composition substudies consistently reveal that 25 to 40% of that weight loss comes from lean mass, not fat.

In the landmark STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 17.3 kg over 68 weeks. Of that, 6.9 kg was lean mass — including muscle tissue critical for metabolic health, cardiovascular fitness, joint protection, and long-term weight maintenance. This represents a rate of lean mass loss roughly equivalent to 20 years of normal aging compressed into 68 weeks of treatment.

Across multiple GLP-1 and GIP/GLP-1 receptor agonist trials, the proportion of weight lost as lean mass ranges from 25% to 40% when measured by dual-energy X-ray absorptiometry (DXA). A 2025 network meta-analysis confirmed that approximately 25% of weight loss was attributable to lean mass loss across various incretin-based therapies.

The primary drivers of this muscle loss are not the drugs themselves, but the consequences of rapid caloric restriction: insufficient protein intake due to appetite suppression, absence of anabolic stimulus from resistance training, and metabolic adaptation to energy deficit. Research shows that GLP-1 users frequently consume far below recommended protein thresholds, with many falling below 60g per day.

Importantly, muscle loss during GLP-1 therapy is not inevitable. A 2025 case series published in PMC demonstrated that patients on semaglutide or tirzepatide who followed structured protein and exercise protocols not only preserved but in some cases increased their lean soft tissue — even during substantial weight loss of up to 33%.

Kiro's Muscle Loss Risk Assessment evaluates five factors consistently identified in the clinical literature as predictors of lean mass loss during GLP-1 treatment: age (sarcopenia risk increases after 50), resistance training frequency (the single most protective factor), daily protein intake relative to body weight, rate of weight loss, and treatment duration.

Each factor is weighted based on effect sizes reported in published trials and reviews. The resulting risk score (low, moderate, or high) generates personalized recommendations that prioritize the most impactful interventions for the user's specific risk profile.

Kiro's AI coach uses these same evidence-based principles to provide daily guidance on protein targets, meal timing around appetite suppression windows, and resistance training integration — adapting recommendations to each user's medication cycle, energy levels, and progress over time.

Kiro's recommendations are derived exclusively from peer-reviewed clinical research published in indexed medical journals. We do not make diagnostic claims, prescribe treatments, or provide medical advice. Our role is to translate published clinical evidence into actionable daily guidance that complements — never replaces — professional medical care.

Our assessment methodology and content are reviewed regularly against emerging research. As new trial data becomes available — including ongoing studies of bimagrumab and other muscle-sparing adjunct therapies — we update our protocols to reflect the current state of evidence.